JAMA Network Open 7(5):e2413172 Valentine WJ, Hoog M, Mody R, Belger M, Pollock R (2023) Long-term cost-effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States
The minimum viable program requires four components: Daily monitoring of Orange Book additions and changes for target product classes, using automated alerts from a platform like DrugPatentWatch rather than periodic manual lookups USPTO continuation application tracking for any product actively in the ANDA development pipeline, with quarterly reviews of relevant patent families FDA Written Request monitoring for pediatric exclusivity signals on pipeline targets PTAB petition docket review for active IPR proceedings against patents the manufacturer is planning to certify against, since a successful IPR petition by another filer can eliminate the patent before the ANDA is even filed What Brand Company IP Teams Miss When They Treat the Orange Book as a Defense Tool Rather Than a Signal Brand companies use the Orange Book to implement evergreening, where they extend market protection by filing follow-on patents on minor modifications
Hence, recent studies have extensively explored the combination of glucose metabolism modulation with chemotherapy
I am grateful and hope my insurance continues to pay for it. She said she knows several people without insurance who rely on compounding pharmacies to buy versions of semaglutide or tirzepatide
Lawaetz, O., Blackburn, A
